Moxiclav (Amoxicillin, Clavulanic Acid)

Amoxicillin, the active ingredient in Moxiclav, is a Penicillin beta-lactam antibiotic presented as an injectable solution for intravenous use. It is combined with clavulanic acid to treat a range of bacterial infections in adult and pediatric patients, including respiratory, urinary, skin and intra‑abdominal infections.

GNH USA supplies Moxiclav as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across global markets, and maintains rigorous quality control with reliable logistics for timely delivery.

Moxiclav is used to treat bacterial infections affecting several organ systems, acting through inhibition of cell‑wall synthesis.

- Respiratory tract infections: effective against community‑acquired pneumonia and sinusitis, reducing bacterial load. - Urinary tract infections: treats uncomplicated and complicated UTIs caused by susceptible organisms. - Skin and soft tissue infections: resolves cellulitis, abscesses and wound infections. - Intra‑abdominal infections: used for peritonitis and intra‑operative infections following abdominal surgery. - Septicemia: provides broad‑spectrum coverage for bloodstream infections caused by susceptible organisms.

Adverse reactions to Moxiclav can range from mild to severe and may require medical attention.

Common Side Effects: - Diarrhea: mild to moderate loose stools. - Nausea: feeling of queasiness. - Vomiting: occasional emesis. - Rash: mild skin erythema. - Elevated liver enzymes: transient increase in transaminases. - Headache: mild to moderate headache. - Injection site pain: local discomfort at infusion site.

Serious or Rare Side Effects: - Anaphylaxis: severe allergic reaction with airway compromise. - Stevens‑Johnson syndrome: rare severe skin and mucosal disorder. - Clostridioides difficile colitis: severe intestinal infection. - Hepatotoxicity: significant liver injury. - Hemolytic anemia: destruction of red blood cells.

Before prescribing Moxiclav, clinicians should consider several safety and handling precautions. - Allergy assessment: avoid in patients with known hypersensitivity to penicillins or β‑lactamase inhibitors. - Renal function: adjust dose in severe renal impairment. - Hepatic impairment: monitor liver function tests during therapy. - Concomitant antibiotics: use caution when combined with other broad‑spectrum agents to prevent overgrowth of resistant flora. - Pregnancy and lactation: evaluate risk‑benefit as safety data are limited. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Moxiclav may interact with other medicines, altering efficacy or increasing toxicity.

Major Interactions (Avoid): - Allopurinol: increased risk of severe skin reactions. - Oral anticoagulants (warfarin): enhanced anticoagulant effect, monitor INR closely.

Moderate Interactions (Monitor Closely): - Methotrexate: reduced renal clearance, monitor serum levels. - Probenecid: decreased renal excretion of amoxicillin, may raise plasma concentrations. - Oral contraceptives: possible reduction in efficacy, advise backup contraception. - Antacids (containing aluminum or magnesium): may reduce amoxicillin absorption, separate dosing by at least 2 hours. - Cimetidine: may increase amoxicillin plasma levels, monitor for toxicity.